Bio Techne Depreciation And Amortization Over Time
| TECH Stock | USD 71.28 0.23 0.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Bio Techne Performance and Bio Techne Correlation. Bio |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Depreciation And Amortization Analysis
Compare Bio Techne Corp and related stocks such as Biomarin Pharmaceutical, Vaxcyte, and Liquidia Technologies Depreciation And Amortization Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMRN | 800 K | 36.1 M | 18.7 M | 47.3 M | 18 M | (17.7 M) | (27 M) | 46.5 M | 48.8 M | 103.2 M | 105.9 M | 108 M | 102 M | 104.4 M | 109.6 M |
| PCVX | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 5.3 M | 1.4 M | 1.8 M | 9.2 M | 3.2 M | 4 M |
| LQDA | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 651.6 K | 931.9 K | 1.5 M | 613.7 K | 3.1 M | 5.8 M | 4 M | 2.2 M | 2.6 M |
| LEGN | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 217 K | 1.7 M | 5.3 M | 9.9 M | 13.9 M | 18.4 M | 20.5 M | 11 M |
| ALNY | 36 K | 5.1 M | 9 M | 10.2 M | 11.9 M | 19.1 M | 15.1 M | 13.4 M | 161.1 K | 54.4 M | 34.8 M | 47.6 M | 44.5 M | 54.1 M | 56.8 M |
| EXEL | 5.7 M | 6.8 M | 5.7 M | 3.1 M | 2.4 M | 1.4 M | 1 M | 1.2 M | 7.8 M | 8.3 M | 9.1 M | 13.6 M | 20.9 M | 25.7 M | 27 M |
| HALO | (54.0) | 1.1 M | 1.1 M | 1.2 M | 1.8 M | 1.7 M | 2.4 M | 2.2 M | 2.4 M | 4.1 M | 3.3 M | 3 M | 49.6 M | 84.9 M | 89.1 M |
| REPL | 122 K | 122 K | 122 K | 122 K | 122 K | 122 K | 122 K | 109 K | 148 K | 533 K | 4.1 M | 4.6 M | 2.4 M | 2.7 M | 2 M |
| NUVL | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | 2.3 M | (306 K) | 8.5 M | 167.9 K | 159.5 K |
| VTYX | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | (1000) | 7 M | 30 K | 470 K | 158 K | 150.1 K |
| ASND | 425 K | 425 K | 425 K | 405 K | 504 K | 558 K | 677 K | 734 K | 880 K | 9.7 M | 8.8 M | 16 M | 17.6 M | 18.9 M | 19.9 M |
| UTHR | (500 K) | 20.5 M | 27.1 M | 31.3 M | 32.2 M | 32.9 M | 31.6 M | 31 M | 35.9 M | 66.8 M | 49.9 M | 49.9 M | 51.3 M | 53.2 M | 55.9 M |
| APLS | 6.3 K | 6.3 K | 6.3 K | 6.3 K | 6.6 K | 53 M | 11.9 K | 11.9 K | 2.9 M | 5.2 M | 859 K | 1.5 M | 1.5 M | 1.7 M | 1.6 M |
| BGNE | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.5 M | 1.9 M | 4.8 M | 10.4 M | 1.3 M | 31.8 M | 46.5 M | 66.3 M | 87.7 M | 92.1 M |
| AKRO | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | (67.9 M) | 17 K | 17 K | 41 K | 260 K | 29 K | 30.4 K |
| BPMC | 501 K | 501 K | 501 K | 501 K | 622 K | 948 K | 1.6 M | 1.6 M | 4.2 M | 10.2 M | 12.3 M | 12.8 M | 20.1 M | 11.7 M | 7.7 M |
| TVTX | 124.9 K | 124.9 K | 124.9 K | 216 K | 5.4 M | 13.4 M | 16.1 M | 17.8 M | 18.7 M | 30.1 M | 25.8 M | 26.6 M | 20.7 M | 38.5 M | 19.6 M |
Bio Techne Corp and related stocks such as Biomarin Pharmaceutical, Vaxcyte, and Liquidia Technologies Depreciation And Amortization description
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.My Equities
My Current Equities and Potential Positions
| Bio Techne Corp | TECH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Minnesota; U.S.A |
| Exchange | NASDAQ Exchange |
USD 71.28
Check out Bio Techne Performance and Bio Techne Correlation. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Bio Techne technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.